Myricetin Inhibited Fear and Anxiety-Like Behaviors by HPA Axis Regulation and Activation of the BDNF-ERK Signaling Pathway in Posttraumatic Stress Disorder Rats.
Journal
Evidence-based complementary and alternative medicine : eCAM
ISSN: 1741-427X
Titre abrégé: Evid Based Complement Alternat Med
Pays: United States
ID NLM: 101215021
Informations de publication
Date de publication:
2022
2022
Historique:
received:
22
12
2021
revised:
16
04
2022
accepted:
23
04
2022
entrez:
20
6
2022
pubmed:
21
6
2022
medline:
21
6
2022
Statut:
epublish
Résumé
Posttraumatic stress disorder (PTSD) is a stress-related psychiatric or mental disorder characterized by experiencing a traumatic stress. The cause of such PTSD is dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis and imbalance of monoamines. Myricetin (MYR) is a common natural flavonoid that has various pharmacological activities. We investigated the effects of MYR on fear, depression, and anxiety following monoamine imbalance and hyperactivation of HPA axis in rats exposed to a single prolonged stress (SPS). Male rats were dosed with MYR (10 and 20 mg/kg, i.p.) once daily for 14 days after exposure to SPS. Administration of MYR reduced freezing responses to extinction recall, depression, and anxiety-like behaviors and decreased increase of plasma corticosterone and adrenocorticotropic hormone levels. Also, administration of MYR restored decreased serotonin and increased norepinephrine in the fear circuit regions, medial prefrontal cortex, and hippocampus. It also increased the reduction in the brain-derived neurotrophic factor (BDNF) and tropomyosin-related kinase B mRNA expression and the ratio of p-ERK/extracellular signal-regulated kinase (ERK) in the hippocampus. Thus, MYR exerted antidepressant and anxiolytic effects by regulation of HPA axis and activation of the BDNF-ERK signaling pathway. Finally, we suggest that MYR could be a useful therapeutic agent to prevent traumatic stress such as PTSD.
Identifiants
pubmed: 35722162
doi: 10.1155/2022/8320256
pmc: PMC9200513
doi:
Types de publication
Journal Article
Langues
eng
Pagination
8320256Informations de copyright
Copyright © 2022 Bongjun Sur and Bombi Lee.
Déclaration de conflit d'intérêts
The authors declare no potential conflicts of interests.
Références
J Affect Disord. 2017 Apr 15;213:1-8
pubmed: 28167453
J Clin Psychiatry. 2004;65 Suppl 1:29-36
pubmed: 14728094
J Neurosci. 2007 Aug 1;27(31):8278-85
pubmed: 17670974
Pharmazie. 2014 Jan;69(1):19-26
pubmed: 24601218
Physiol Behav. 2012 Jan 18;105(2):408-16
pubmed: 21925525
Learn Mem. 2016 Nov 15;23(12):689-698
pubmed: 27918273
Behav Sleep Med. 2021 Mar-Apr;19(2):208-220
pubmed: 32063030
Psychopharmacology (Berl). 2004 Mar;172(2):225-9
pubmed: 14586539
Horm Behav. 2018 Jul;103:7-18
pubmed: 29802874
Mol Psychiatry. 2007 Jun;12(6):522-43
pubmed: 17160067
Mol Psychiatry. 2014 Sep;19(9):1001-9
pubmed: 24126929
Behav Brain Res. 2020 Oct 1;395:112867
pubmed: 32827567
Biomed Pharmacother. 2017 Jul;91:378-384
pubmed: 28463801
Psychiatriki. 2020 Apr-Jun;31(2):162-171
pubmed: 32840220
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Dec 1;35(8):1810-9
pubmed: 21925230
Harv Rev Psychiatry. 2018 May/Jun;26(3):116-128
pubmed: 29734226
Curr Top Behav Neurosci. 2019;43:271-321
pubmed: 30357573
Front Psychiatry. 2018 May 15;9:196
pubmed: 29867615
J Neuroendocrinol. 2009 Nov;21(11):898-909
pubmed: 19732290
Brain Res. 2003 May 2;971(1):55-65
pubmed: 12691837
Food Funct. 2016 Jun 15;7(6):2624-34
pubmed: 27171848
J Sports Med Phys Fitness. 2020 Jan;60(1):172-179
pubmed: 32008312
PLoS One. 2016 Sep 07;11(9):e0160923
pubmed: 27603014
Int Immunopharmacol. 2019 Oct;75:105742
pubmed: 31325727
Int J Psychiatry Med. 2014;47(4):337-46
pubmed: 25084856
Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):169-80
pubmed: 19141307
Neurosci Biobehav Rev. 2016 Dec;71:48-57
pubmed: 27590828
Neurobiol Learn Mem. 2017 Oct;144:248-258
pubmed: 28818702
Int J Mol Sci. 2018 Dec 03;19(12):
pubmed: 30513893
Nutrients. 2016 Feb 16;8(2):90
pubmed: 26891321
Behav Brain Res. 2015 Jul 15;288:39-49
pubmed: 25882722
J Occup Rehabil. 2015 Sep;25(3):569-76
pubmed: 25573017
Psychopharmacology (Berl). 2019 Jan;236(1):183-199
pubmed: 30610352
Neurobiol Learn Mem. 2016 Apr;130:26-33
pubmed: 26808441
Biomolecules. 2019 Mar 12;9(3):
pubmed: 30871113
Korean J Physiol Pharmacol. 2016 Jul;20(4):357-66
pubmed: 27382352
Korean J Physiol Pharmacol. 2017 Nov;21(6):579-589
pubmed: 29200900
J Ginseng Res. 2020 Jul;44(4):644-654
pubmed: 32617045
Physiol Behav. 2014 May 10;130:47-53
pubmed: 24657739
Psychopharmacology (Berl). 2019 Jan;236(1):49-57
pubmed: 30374892
Int J Mol Sci. 2010 Nov 02;11(11):4348-60
pubmed: 21151442
Mol Med Rep. 2018 Feb;17(2):3274-3280
pubmed: 29257250
Learn Mem. 2012 Jan 12;19(2):43-9
pubmed: 22240323
Neuropharmacology. 2014 Jan;76 Pt C:696-708
pubmed: 23660230
Biomed Pharmacother. 2020 Jul;127:110194
pubmed: 32371315
Neural Regen Res. 2016 Dec;11(12):1976-1980
pubmed: 28197195
Exp Ther Med. 2019 Apr;17(4):3083-3091
pubmed: 30906480
Neurobiol Learn Mem. 2017 Mar;139:165-178
pubmed: 28137660
Biol Psychiatry. 2007 Apr 15;61(8):966-73
pubmed: 17137559
Behav Brain Res. 2019 Oct 17;372:112055
pubmed: 31233821
Brain Res. 2009 Oct 13;1293:13-23
pubmed: 19332037
Korean J Physiol Pharmacol. 2018 Sep;22(5):525-538
pubmed: 30181699
Behav Brain Res. 2015 Jun 1;286:256-64
pubmed: 25746511